Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-017994
Filing Date
2023-11-07
Accepted
2023-11-07 16:12:54
Documents
64
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q olma-20230930x10q.htm   iXBRL 10-Q 1963698
2 EX-31.1 olma-20230930xex31d1.htm EX-31.1 13573
3 EX-31.2 olma-20230930xex31d2.htm EX-31.2 13623
4 EX-32.1 olma-20230930xex32d1.htm EX-32.1 10476
  Complete submission text file 0001558370-23-017994.txt   6808959

Data Files

Seq Description Document Type Size
5 EX-101.SCH olma-20230930.xsd EX-101.SCH 40713
6 EX-101.CAL olma-20230930_cal.xml EX-101.CAL 49511
7 EX-101.DEF olma-20230930_def.xml EX-101.DEF 132434
8 EX-101.LAB olma-20230930_lab.xml EX-101.LAB 402051
9 EX-101.PRE olma-20230930_pre.xml EX-101.PRE 286529
58 EXTRACTED XBRL INSTANCE DOCUMENT olma-20230930x10q_htm.xml XML 1064481
Mailing Address 780 BRANNAN STREET SAN FRANCISCO CA 94103
Business Address 780 BRANNAN STREET SAN FRANCISCO CA 94103 (415) 651-3316
Olema Pharmaceuticals, Inc. (Filer) CIK: 0001750284 (see all company filings)

EIN.: 300409740 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39712 | Film No.: 231384063
SIC: 2834 Pharmaceutical Preparations